INMB
INmune Bio, Inc.
There isn't enough reported data to score INMB yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
INMB Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Unavailable | |
| Unavailable |
INMB's revenue is currently strong, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
INMB PE Valuation
INMB has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
INMB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect INMB's revenue to decline, with its earnings and profitability holding steady.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
INMB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.56 | +$1.56 |
| Q2 2026 | -$0.63 | +$1.85 |
| Q1 2026 | -$1.63 | +$0.30 |
| Q4 2025 | -$1.86 | +$0.25 |
| Q3 2025 | -$2.12 | +$0.06 |
| Q2 2025 | -$2.48 | -$0.42 |
| Q1 2025 | -$1.93 | -$0.01 |
| Q4 2024 | -$2.11 | -$0.44 |
INMB is still losing money, but far less than before: $0.56 per share over the past year, against $2.48 at its worst in mid-2025.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over INMB on earnings quality, reporting a profit while its opponent remains loss making.
INMB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2025 | $50K | +257% |
| Q1 2024 | $14K | -63% |
| Q4 2023 | $28K | -71% |
| Q3 2023 | $43K | -56% |
| Q2 2023 | $46K | +188% |
| Q1 2023 | $38K | -77% |
| Q4 2022 | $97K | -40% |
| Q3 2022 | $98K | +600% |
INMB's revenue is growing: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2025 | -19810% | +58883 points |
| Q1 2024 | -78693% | -61790 points |
| Q4 2023 | -29925% | -24109 points |
| Q3 2023 | -19833% | -12238 points |
| Q2 2023 | -13937% | +25988 points |
| Q1 2023 | -16903% | -12928 points |
| Q4 2022 | -5816% | -277 points |
| Q3 2022 | -7595% | +56841 points |
INMB's operating margin was −19810% last quarter, down 5873 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
INMB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.4M | +$2.2M |
| Q1 2026 | -$3.4M | +$3.4M |
| Q4 2025 | -$3.1M | +$7.9M |
| Q3 2025 | -$5.6M | +$1.4M |
| Q1 2025 | -$6.8M | +$652K |
| Q4 2024 | -$11M | -$7.6M |
| Q3 2024 | -$7M | -$2.7M |
| Q2 2024 | -$7.9M | -$4.7M |
INMB has burned cash in almost every quarter: −$13M over the past year, against −$30M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over INMB on cash generation, producing positive trailing cash flow while its opponent burns cash.
INMB Net Leverage
INMB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
INMB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.4 | Neutral |
| Stochastic | 3.7 | Oversold |
INMB's weekly RSI is 32 (neutral) and its Stochastic is 4 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
INMB PE vs Healthcare Sector
INMB has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
INMB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.56 | 33% below |
| 20 week MA | $1.87 | 44% below |
| 50 week MA | $1.63 | 36% below |
| 100 week MA | $3.33 | 68% below |
| 200 week MA | $5.90 | 82% below |
INMB is in a downtrend: it's below all five of its weekly moving averages, and 82% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over INMB on trend strength, trading above more of its moving averages.
INMB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.35 | $12.8 | +138% |
| 2021 | $12.8 | $10.9 | -15% |
| 2022 | $10.9 | $7.03 | -35% |
| 2023 | $7.03 | $11.3 | +60% |
| 2024 | $11.3 | $4.65 | -59% |
| 2025 | $4.65 | $1.73 | -63% |
| 2026 YTD | $1.73 | $1.05 | -39% |
INMB's yearly returns have swung widely, from +138% in 2020 to −63% in 2025. It's down 39% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over INMB on returns for 2026, with the stronger performance.